{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:30Z","timestamp":1792027530376,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05329-4","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:13:12Z","timestamp":1786187592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, safety, and quality of life outcomes of [177Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis"],"prefix":"10.1007","author":[{"given":"Moosa","family":"Mubarika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Maaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awon","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Emmama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaroon","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0717-2777","authenticated-orcid":false,"given":"Muddassir","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiya","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hisham","family":"Alamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biruk Demisse","family":"Ayalew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb","family":"Khawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hussnain","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam M. S.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"3","key":"5329_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3322\/caac.21884","volume":"73","author":"H Sung","year":"2023","unstructured":"Sung H, Ferlay J, Siegel RL et al (2023) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 73(3):161\u2013185. https:\/\/doi.org\/10.3322\/caac.21884","journal-title":"CA Cancer J Clin"},{"issue":"10228","key":"5329_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa1911440","volume":"395","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 395(10228):1495\u20131508. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"issue":"11","key":"5329_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Herrmann K, Calais J et al (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58(11):1715\u20131720. https:\/\/doi.org\/10.2967\/jnumed.116.186767","journal-title":"J Nucl Med"},{"issue":"6","key":"5329_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00259-017-3666-0","volume":"44","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C et al (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Eur J Nucl Med Mol Imaging 44(6):949\u2013958. https:\/\/doi.org\/10.1007\/s00259-017-3666-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"5329_CR5","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2967\/jnumed.120.254466","volume":"62","author":"H Ahmadzadehfar","year":"2021","unstructured":"Ahmadzadehfar H, Fimmers R, Yordanova A et al (2021) The impact of the number of cycles and baseline parameters on overall survival and PSA response to [177Lu]Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med 62(10):1418\u20131426. https:\/\/doi.org\/10.2967\/jnumed.120.254466","journal-title":"J Nucl Med"},{"issue":"12","key":"5329_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"5329_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"1","key":"5329_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"5329_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5329_CR10","doi-asserted-by":"publisher","first-page":"e8109","DOI":"10.5867\/medwave.2021.02.8109","volume":"21","author":"M Kirmayr","year":"2021","unstructured":"Kirmayr M, Quilodr\u00e1n C, Valente B, Loezar C, Garegnani L, Franco JVA (2021) The GRADE approach, part 1: how to assess the certainty of the evidence. Medwave 21:e8109. https:\/\/doi.org\/10.5867\/medwave.2021.02.8109","journal-title":"Medwave"},{"issue":"1","key":"5329_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61(1):64\u201375. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.013","journal-title":"J Clin Epidemiol"},{"issue":"10459","key":"5329_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K et al (2024) 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404(10459):1227\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2","journal-title":"Lancet"},{"issue":"5","key":"5329_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","volume":"49","author":"S Satapathy","year":"2022","unstructured":"Satapathy S, Mittal BR, Sood A et al (2022) 177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial. Eur J Nucl Med Mol Imaging 49(5):1754\u20131764. https:\/\/doi.org\/10.1007\/s00259-021-05618-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5329_CR14","unstructured":"Sartor O. Study evaluating mCRPC treatment using PSMA [Lu-177]-PNT2002 therapy after second-line hormonal treatment (SPLASH). ClinicalTrials.gov. Updated January 13, 2026. Accessed March 5, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04647526"},{"issue":"5","key":"5329_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)0135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M et al (2024) [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25(5):563\u2013571. https:\/\/doi.org\/10.1016\/S1470-2045(24)0135-9","journal-title":"Lancet Oncol"},{"issue":"10276","key":"5329_CR16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"issue":"5","key":"5329_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102398","volume":"23","author":"Z Belabaci","year":"2025","unstructured":"Belabaci Z, Sleiay M, Abdelshafi A et al (2025) Safety and efficacy of lutetium-177 PSMA therapy for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Clin Genitourin Cancer 23(5):102398. https:\/\/doi.org\/10.1016\/j.clgc.2025.102398","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"5329_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA et al (2023) Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther 23(7):731\u2013744. https:\/\/doi.org\/10.1080\/14737140.2023.2213892","journal-title":"Expert Rev Anticancer Ther"},{"issue":"14","key":"5329_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147431","volume":"22","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska M, Fragoso Costa P, Eiber M et al (2021) Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int J Mol Sci 22(14):7431. https:\/\/doi.org\/10.3390\/ijms22147431","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5329_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"12","key":"5329_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402\u20131418. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702","journal-title":"J Clin Oncol"},{"issue":"2","key":"5329_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/AJR.18.20845","volume":"213","author":"MP Yadav","year":"2019","unstructured":"Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C (2019) Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 213(2):275\u2013285. https:\/\/doi.org\/10.2214\/AJR.18.20845","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"5329_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11523-024-01117-1","volume":"20","author":"C Ciccarese","year":"2025","unstructured":"Ciccarese C, Bauckneht M, Zagaria L et al (2025) Defining the position of [177Lu]Lu-PSMA radioligand therapy in the treatment landscape of metastatic castration-resistant prostate cancer: a meta-analysis of clinical trials. Target Oncol 20(1):103\u2013112. https:\/\/doi.org\/10.1007\/s11523-024-01117-1","journal-title":"Target Oncol"},{"issue":"6","key":"5329_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.euo.2018.11.005","volume":"2","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Lin P, Higano CS et al (2019) Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. Eur Urol Oncol 2(6):677\u2013684. https:\/\/doi.org\/10.1016\/j.euo.2018.11.005","journal-title":"Eur Urol Oncol"},{"key":"5329_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2025.03.019","author":"M Miszczyk","year":"2025","unstructured":"Miszczyk M, Fazekas T, Rajwa P et al (2025) Prostate-specific antigen response as a prognostic factor for overall survival in patients with prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis. Eur Urol Focus. https:\/\/doi.org\/10.1016\/j.euf.2025.03.019","journal-title":"Eur Urol Focus"},{"issue":"2","key":"5329_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/pcan.2014.53","volume":"18","author":"HH Cheng","year":"2015","unstructured":"Cheng HH, Gulati R, Azad A et al (2015) Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel. Prostate Cancer Prostatic Dis 18(2):122\u2013127. https:\/\/doi.org\/10.1038\/pcan.2014.53","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"suppl 1","key":"5329_CR27","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/pros.24356","volume":"82","author":"EM Kwan","year":"2022","unstructured":"Kwan EM, Wyatt AW (2022) Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate 82(suppl 1):S25\u2013S36. https:\/\/doi.org\/10.1002\/pros.24356","journal-title":"Prostate"},{"issue":"1","key":"5329_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-025-01229-3","volume":"15","author":"S Yadav","year":"2025","unstructured":"Yadav S, Tuchayi AM, Moradpour M et al (2025) Pre- or post-chemotherapy: effect on PSMA uptake. EJNMMI Res 15(1):36. https:\/\/doi.org\/10.1186\/s13550-025-01229-3","journal-title":"EJNMMI Res"},{"issue":"6","key":"5329_CR29","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00259-025-07076-7","volume":"52","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Hoeh B, Siech C et al (2025) Lutetium-177 PSMA radioligand therapy in taxane-naive first- and second-line metastatic castration-resistant prostate cancer after first-line ARPI therapy. Eur J Nucl Med Mol Imaging 52(6):2015\u20132022. https:\/\/doi.org\/10.1007\/s00259-025-07076-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"28","key":"5329_CR30","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1200\/JCO.2005.06.679","volume":"23","author":"MI Zia","year":"2005","unstructured":"Zia MI, Siu LL, Pond GR, Chen EX (2005) Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens. J Clin Oncol 23(28):6982\u20136991. https:\/\/doi.org\/10.1200\/JCO.2005.06.679","journal-title":"J Clin Oncol"},{"issue":"22","key":"5329_CR31","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1200\/JCO.2008.16.1711","volume":"26","author":"LE Dodd","year":"2008","unstructured":"Dodd LE, Korn EL, Freidlin B et al (2008) Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26(22):3791\u20133796. https:\/\/doi.org\/10.1200\/JCO.2008.16.1711","journal-title":"J Clin Oncol"},{"key":"5329_CR32","unstructured":"Pluvicto (lutetium Lu 177 vipivotide tetraxetan) [prescribing information]. US Food and Drug Administration; 2022. Accessed March 5, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf"},{"issue":"5","key":"5329_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/j.1524-4733.2007.00195.x","volume":"10","author":"EQ Wu","year":"2007","unstructured":"Wu EQ, Mulani P, Farrell MH, Sleep D (2007) Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 10(5):408\u2013414. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00195.x","journal-title":"Value Health"},{"issue":"4","key":"5329_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","volume":"87","author":"YH Dai","year":"2025","unstructured":"Dai YH, Chen PH, Lee DJ et al (2025) A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilizing lutetium-177 and actinium-225 in metastatic prostate cancer. Eur Urol 87(4):398\u2013408. https:\/\/doi.org\/10.1016\/j.eururo.2024.09.020","journal-title":"Eur Urol"},{"issue":"1","key":"5329_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","volume":"12","author":"D Cella","year":"2009","unstructured":"Cella D, Nichol MB, Eton D, Nelson JB, Mulani P (2009) Estimating clinically meaningful changes for the functional assessment of cancer therapy\u2013prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health 12(1):124\u2013129. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00409.x","journal-title":"Value Health"},{"issue":"1","key":"5329_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA et al (2021) A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177\u2013labeled prostate-specific membrane antigen\u2013targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol 80(1):82\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.004","journal-title":"Eur Urol"},{"issue":"6","key":"5329_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2967\/jnumed.115.156133","volume":"56","author":"K Herrmann","year":"2015","unstructured":"Herrmann K, Bluemel C, Weineisen M et al (2015) Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med 56(6):855\u2013861. https:\/\/doi.org\/10.2967\/jnumed.115.156133","journal-title":"J Nucl Med"},{"issue":"1","key":"5329_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00805-7","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J et al (2021) Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res 11(1):61. https:\/\/doi.org\/10.1186\/s13550-021-00805-7","journal-title":"EJNMMI Res"},{"issue":"4","key":"5329_CR39","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.eururo.2023.12.004","volume":"85","author":"KN Chi","year":"2024","unstructured":"Chi KN, Armstrong AJ, Krause BJ et al (2024) Safety analyses of the phase 3 VISION trial of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur Urol 85(4):382\u2013391. https:\/\/doi.org\/10.1016\/j.eururo.2023.12.004","journal-title":"Eur Urol"},{"issue":"12","key":"5329_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123020","volume":"10","author":"S van der Gaag","year":"2022","unstructured":"van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H (2022) Pharmacological optimization of PSMA-based radioligand therapy. Biomedicines 10(12):3020. https:\/\/doi.org\/10.3390\/biomedicines10123020","journal-title":"Biomedicines"},{"issue":"22","key":"5329_CR41","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K et al (2020) Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 382(22):2091\u20132102. https:\/\/doi.org\/10.1056\/NEJMoa1911440","journal-title":"N Engl J Med"},{"issue":"1","key":"5329_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00259-025-07438-1","volume":"53","author":"Z Belabaci","year":"2025","unstructured":"Belabaci Z, Schmidt L, Sleiay M, Cou\u00f1ago F, L\u00f3pez Campos F, Tolba M et al (2025) Efficacy and safety of rechallenge therapy with [1\u2077\u2077Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 53(1):93\u2013104. https:\/\/doi.org\/10.1007\/s00259-025-07438-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5329_CR43","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00259-025-07627-y","volume":"53","author":"Z Belabaci","year":"2026","unstructured":"Belabaci Z, Brignoli G, Zilli T, Gruji\u0107 M, Mohamad I, Al-Ibraheem A et al (2026) Therapeutic outcomes of 225Ac\/1\u2077\u2077Lu-PSMA combination therapy in advanced metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 53(5):2881\u20132892. https:\/\/doi.org\/10.1007\/s00259-025-07627-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5329_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fnume.2023.1291253","volume":"3","author":"C Meyer","year":"2023","unstructured":"Meyer C, Szidonya L, Winters C et al (2023) Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry. Front Nucl Med 3:1291253. https:\/\/doi.org\/10.3389\/fnume.2023.1291253","journal-title":"Front Nucl Med"},{"key":"5329_CR45","doi-asserted-by":"publisher","DOI":"10.4274\/uob.galenos.2023.2023.8.2","author":"B Sen","year":"2023","unstructured":"Sen B, \u00d6zkan E, K\u00fc\u00e7\u00fck N (2023) PSMA targeted ligands in imaging and theranostics for prostate cancer. Bull Urooncol. https:\/\/doi.org\/10.4274\/uob.galenos.2023.2023.8.2","journal-title":"Bull Urooncol"},{"issue":"2","key":"5329_CR46","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC et al (2017) Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med 58(2):312\u2013319. https:\/\/doi.org\/10.2967\/jnumed.116.178228","journal-title":"J Nucl Med"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05329-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05329-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T11:13:14Z","timestamp":1786187594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05329-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":46,"alternative-id":["5329"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05329-4","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could influence the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable. This study is a systematic review and meta-analysis of previously published studies. As such, it did not involve direct contact with human or animal subjects, and ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review and meta-analysis of previously published, aggregated data. No primary patient data was collected and, therefore, patient consent was not required.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}